Aileron Therapeutics, Inc. (NASDAQ:ALRN) has earned an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus price target of $19.33 for the company, according to Zacks. Zacks has also given Aileron Therapeutics an industry rank of 104 out of 265 based on the ratings given to its competitors.

A number of equities analysts recently issued reports on ALRN shares. Canaccord Genuity started coverage on Aileron Therapeutics in a report on Monday, July 24th. They issued a “buy” rating and a $19.00 price target for the company. William Blair started coverage on Aileron Therapeutics in a report on Monday, July 24th. They issued an “outperform” rating for the company. Jefferies Group LLC started coverage on Aileron Therapeutics in a report on Monday, July 24th. They issued a “buy” rating and a $20.00 price target for the company. Finally, Bank of America Corporation assumed coverage on Aileron Therapeutics in a report on Monday, July 24th. They issued a “buy” rating and a $19.00 price target for the company.

TRADEMARK VIOLATION WARNING: “Zacks: Aileron Therapeutics, Inc. (ALRN) Receives Average Rating of “Strong Buy” from Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/08/zacks-aileron-therapeutics-inc-alrn-receives-average-rating-of-strong-buy-from-analysts.html.

Aileron Therapeutics (ALRN) opened at 14.06 on Friday. The stock’s market capitalization is $206.89 million. Aileron Therapeutics has a 12 month low of $10.37 and a 12 month high of $14.32. The company has a 50 day moving average of $12.41 and a 200 day moving average of $12.55.

In other news, major shareholder Cvf, Llc acquired 180,000 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was acquired at an average cost of $15.00 per share, with a total value of $2,700,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Reinhard J. Ambros acquired 266,667 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was purchased at an average cost of $15.00 per share, with a total value of $4,000,005.00. The disclosure for this purchase can be found here. Insiders bought 696,667 shares of company stock valued at $10,450,005 over the last three months. Corporate insiders own 68.10% of the company’s stock.

Several hedge funds have recently bought and sold shares of ALRN. Jennison Associates LLC acquired a new stake in shares of Aileron Therapeutics in the second quarter valued at approximately $2,788,000. Candriam Luxembourg S.C.A. acquired a new stake in shares of Aileron Therapeutics in the second quarter valued at approximately $1,673,000. Sphera Funds Management LTD. acquired a new stake in shares of Aileron Therapeutics in the second quarter valued at approximately $1,394,000. Nexthera Capital LP acquired a new stake in shares of Aileron Therapeutics in the second quarter valued at approximately $1,272,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Aileron Therapeutics in the second quarter valued at approximately $418,000. 12.30% of the stock is owned by institutional investors and hedge funds.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.